Ischemic Stroke
Pipeline by Development Stage
Drug Modality Breakdown
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
Competitive Landscape
67 companies ranked by most advanced pipeline stage
+37 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 22,240 patients across 50 trials
Reducing Intracranial atheroSclErosis With Repatha
Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
Assess the Penumbra System in the Treatment of Acute Stroke
Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)
Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke
Butylphthalide for Long-term Efficacy in Minor Stroke Study
Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke
Combination of Hypothermia and Thrombectomy in Acute Stroke
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
Tenecteplase in Wake-up Ischaemic Stroke Trial
Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke
Effect of F2695 on Functional Recovery After Ischemic Stroke
Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
Enhancing Rehabilitation After Stroke
hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP)
Japan Statin Treatment Against Recurrent Stroke (J-STARS)
Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo)
Phase 2 Study of TXA127 in Post-ischemic Stroke Patients
BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome
Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke
Investigation of Neural Stem Cells in Ischemic Stroke
Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance
REperfusion With Cooling in CerebraL Acute IscheMia II
Safety Evaluation of 3K3A-APC in Ischemic Stroke
Hypothermia in Acute Ischemic Stroke - Surface Versus Endovascular Cooling (HAIS-SE)
A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Brain.Pad (iCOOL 3)
Study to Examine the Effects of MultiStem in Ischemic Stroke
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. RhinoChill (iCOOL 1)
Safety of Intravenous Thrombolysis for Wake-up Stroke
Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke
The Safety and Efficacy of NouvSoma001 in Ischemic Stroke
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
IVIG in Acute Ischemic Stroke: A Pilot Study
A Safety Evaluation of the Use of Magnetic-guided Iron Particles
Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients
Continuous Dual Aspiration Technique With Zoom System for Stroke
StrokeNet Thrombectomy Endovascular Platform
A Trial of Rehabilitation Paired with VNS for Motor Function in Patients with Stroke (Repair Study)
Post-Stroke Sensory Reweighting on Walking and Balance Outcomes
Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke
EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment
Australasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
Obstructive Sleep Apnea Treatment From Acute to Chronic Phase of Stroke
Gravity Stent-Retriever System For Reperfusion Of Large Vessel Occlusion Stroke Trial
VNS-REHAB At-Home - Post-Market Study for Using the Vivistim System® at Home
Long-Term Safety Study of CTX0E03 in Subjects Who Completed PISCES III Study
Related Jobs in Neurology
Sr Commercial Excellence Manager, Stroke
Sr Software Engineer, User Facing Applications
Staff Manufacturing Engineer, Consumables
Executive Associate II, Neuroscience GPLs
Director, Program Management, Neuroscience
Senior Therapeutic Area Specialist, Neurology/MS – Orlando, FL
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.